35 / 86
Patient Characteristics
Category
Subgroup
Eribulin (n=228)
n (%)
Dacarbazine (n=224)
n (%)
Age
<65 years
≥65 years
178 (78.1)
50 (21.9)
178 (79.5)
46 (20.5)
Sex
Female
161 (70.6)
142 (63.4)
Race
White
Black or African American
Asian*
Other/NA
162 (71.1)
6 (2.6)
18 (7.9)
42 (18.4)
168 (75.0)
6 (2.7)
16 (7.1)
34 (15.2)
ECOG PS
0
1
2
111 (48.7)
114 (50.0)
3 (1.3)
90 (40.2)
121 (54.0)
13 (5.8)
Geographic
region
†
Region 1
Region 2
Region 3
87 (38.2)
106 (46.5)
35 (15.4)
86 (38.4)
105 (46.9)
33 (14.7)
There were no significant differences in baseline characteristics between the 2 treatment
arms
1. Schöffski P, et al. Presented at ASCO 2015 Annual Meeting, Chicago IL, June 3-7, 2015:abstr LBA10502
2. Schöffski P, et al. Lancet. 2016 Apr 16;387(10028):1629-37